497 results on '"Ribaudo, Heather J"'
Search Results
102. Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure
103. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness: AIDS Clinical Trial Group Study A5260s
104. CHANGES IN BODY MASS INDEX WITH INTEGRASE INHIBITOR USE IN REPRIEVE.
105. A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection.
106. A Phase III Comparative Study of the Efficacy and Tolerability of Three Non-Nucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naïve HIV-1-Infected Volunteers: A Randomized, Controlled Trial
107. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial
108. Changes in Plasma Levels of Oxidized Lipoproteins and Lipoprotein Subfractions with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy and Associations with Common Carotid Artery Intima-Media Thickness: ACTG 5260s
109. Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols
110. Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols
111. Vitamin D does not Modulate Immune-Mediated Bone loss during ART Initiation
112. Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity
113. Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols
114. Pre‐existing Minority Drug‐Resistant HIV‐1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure
115. IMPACT OF COVID-19 AND HOST FACTORS ON THE HUMORAL IMMUNE REPERTOIRE IN TREATED HIV.
116. BASELINE AND TEMPORAL DIFFERENCES IN PROTEOMICS FOLLOWING SARS-CoV-2 INFECTION IN PWH.
117. Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection
118. PROSPECTIVE RANDOMIZED CLINICAL TRIAL OF THE EFFECTS OF THREE MODERN ANTIRETROVIRAL THERAPIES ON CAROTID INTIMA-MEDIA THICKNESS IN HIV-INFECTED INDIVIDUALS (AIDS CLINICAL TRIALS GROUP STUDY A5260S)
119. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure
120. Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study
121. Body Composition, Soluble Markers of Inflammation, and Bone Mineral Density in Antiretroviral Therapy–Naive HIV-1–Infected Individuals
122. Cost-Effectiveness Analysis of Ugt1A1 Genetic Testing to Inform Antiretroviral Prescribing in HIV Disease
123. Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257.
124. Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure
125. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants
126. Hyperlipidaemia in HIV-Infected Patients on Lopinavir/Ritonavir Monotherapy in Resource-Limited Settings
127. Comparative Effectiveness of Initial Antiretroviral Therapy Regimens
128. Change in High-Sensitivity C-Reactive Protein Levels Following Initiation of Efavirenz-Based Antiretroviral Regimens in HIV-Infected Individuals
129. Effect ofCYP2B6,ABCB1, andCYP3A5Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study
130. Ultrasensitive Detection of Minor Drug-Resistant Variants for HIV After Nevirapine Exposure Using Allele-Specific PCR: Clinical Significance
131. Racial Differences in Virologic Failure Associated With Adherence and Quality of Life on Efavirenz-Containing Regimens for Initial HIV Therapy
132. Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation.
133. Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.
134. Design Issues in Initial HIV-Treatment Trials: Focus on Actg A5095
135. Differential CD4+cell count increase and CD4+ : CD8+ratio normalization with maraviroc compared with tenofovir
136. A joint analysis of quality of life and survival using a random effect selection model
137. A Multilevel Analysis of Longitudinal Ordinal Data: Evaluation of the Level of Physical Performance of Women Receiving Adjuvant Therapy for Breast Cancer
138. Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-Boosted Atazanavir in AIDS Clinical Trials Group Study A5202.
139. No Risk of Myocardial Infarction Associated With Initial Antiretroviral Treatment Containing Abacavir: Short and Long-Term Results from ACTG A5001/ALLRT.
140. Metabolic Effects of Protease Inhibitor—Sparing Anti retroviral Regimens Given as InitialTreatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
141. What have we learned from the REPRIEVE trial and where do we go from here?
142. Cost-Effectiveness Analysis of Ugt1A1Genetic Testing to Inform Antiretroviral Prescribing in HIV Disease
143. Differential Levels of Soluble Inflammatory Markers by Human Immunodeficiency Virus Controller Status and Demographics
144. Design Issues in Initial HIV-Treatment Trials: Focus on Actg A5095
145. Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.
146. Birth Weight for Gestational Age Norms for a Large Cohort of Infants Born to HIV-Negative Women in Botswana Compared with Norms for U.S.-Born Black Infants
147. Reply to Tong et al.
148. Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure
149. Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE Cohort.
150. Coronary Artery Plaque Composition and Severity Relate to the Inflammasome in People With Treated Human Immunodeficiency Virus.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.